Aspire Biopharma Holdings, Inc. Common Stock
Here’s whether Aspire Biopharma Holdings, Inc. Common Stock (ASBP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+38.86% over 10 days); RSI 47 — healthy momentum range; 3-month momentum positive (+408.8%); rising volume confirms the move (1.22x 30d avg). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -67.4%. Currently 85.8% off its 52-week high. Score: +2/7.
ASBP is trading below its 200-day MA ($6.26) — a key warning sign the longer-term trend is under pressure. An RSI of 46.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -67.4% compares to +22.9% for SPY (trailed the market by 90.2%). The current 85.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.